Temporary bilateral central scotoma under scotopic conditions associated with oral semaglutide

Peter Bracha, MD(1), William Johnson, MD(1), Sabrina Chu, BS (2), James Davison, MD, FACS(1)
1Wolfe Eye Clinic, West Des Moines, Iowa, USA
2Des Moines University College of Osteopathic Medicine, Des Moines, Iowa, USA

DES MOINES UNIVERSITY
MEDICINE & HEALTH SCIENCES

Introduction

- Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP1-RA) that treats type 2 diabetes mellitus
- It can also be used as an adjunct for weight loss when combined with exercise and diet.[1,2]
- One ophthalmic side effect of semaglutide and similar GLP1-RAs is a paradoxical increase in diabetic retinopathy.[4,5]
- Here we report a case of a central, bilateral visual scotoma under scotopic conditions in a board-certified ophthalmologist, that resolved quickly following medication discontinuation. To our knowledge no prior similar case has been reported.

Case Description

- Patient presentation: A 72-year-old healthy board-certified male ophthalmologist had a history of cataract surgery right eye (OD) 18 months earlier and a mild nuclear cataract on the left eye (OS) when he started taking oral semaglutide to help with weight loss. His medications included oral semaglutide 3 mg daily for 20 days, propranolol 20 mg twice a day, aspirin 81 mg daily, naproxen 220 mg and ibuprofen 400 mg as needed.
- 17 days after starting 3.0 mg oral semaglutide (Rybelsus) daily he observed a small, round central scotoma OD (Figures 1 and 2). It appeared to enlarge over three evenings of observation, ultimately turning into an irregular square shape (Figure 3).
- These symptoms were observed during the night and disappeared with natural or artificial light the next morning. When closing his eyes, a bright white afterimage of the dark scotoma faded over 5 seconds. When entering a partially lit bathroom, the scotoma took on a dark brown appearance for a fraction of a second and then disappeared.
- After three days a similar but smaller scotoma was detected OS. That next morning, the medication was discontinued. The symptoms gradually diminished over the next two evenings and dissipated. The timing of symptoms are summarized in Table 1.
- The patient returned from his vacation, upon which a formal ophthalmic evaluation was performed with unremarkable findings.
  - His uncorrected distance visual acuity measured 20/20 OD and 20/25 OS.
  - The anterior segment exam was normal including a well-centered intraocular lens and clear posterior capsule.
  - Fundus examination, Humphrey visual field testing, and Macular optical coherence tomography findings can be summarized in figures 4, 5, and 6. Retinal nerve fiber layer OCTs were normal.

Figures

Figure 1: Patient drawing of a dim scotoma under scotopic condition covering the central portion of a ceiling fan.

Figure 2. Patient drawing of the dim scotoma projected over a portion of bedside table lamp shade. The scotoma could be projected anywhere in the room.

Figure 3. The scotoma grew over several evenings and became an irregular square-shape while the relative dimness of the scotoma remained unchanged.



Figure 5. Humphrey visual fields reveal symmetrically normal highly reliable results for both eyes.



Figure 4. Optos fundus photography of both eyes demonstrating a mostly benign appearance with a few drusen in both eyes and a PVD in the left eye.



Figure 6. Macular OCTs demonstrate symmetrically minimal small drusen in with normal foveal contours.

Timeline

Date	Event
Day 0	Started 3.0 mg semaglutide in the morning
Day 16	First noticed right eye round, central scotoma
Day 17	Noticed enlarging square shape scotoma including and just below fixation
Day 19	Noticed a minimal, small and round scotoma in the left eye
Day 20	Discontinued semaglutide with 9 doses remaining (20 days total)
Day 21	Round scotoma
Day 22	Notices an enlarged scotoma covering a door panel
Day 23	Residual scotoma remaining
Day 24	Scotoma is gone

Discussion

- Here we report a case of an actively practicing cataract/refractive ophthalmologist who developed a bilateral, incongruous reversible central scotoma observed only under scotopic conditions while taking semaglutide.
- The one known retinal side effect of semaglutide is the paradoxical worsening of diabetic retinopathy, which is not applicable here as the subject didn't have diabetes or retinopathy.
- We postulate that the primary location of pathology in our patient may be neurosensory in nature produced by dysfunction of retinal ganglion cells.
- Supporting a possible optic neuropathy cause is the distribution of GLP-1 receptors in the human retina. Some evidence localizes GLP1 receptors primarily to the retinal ganglion cells with minimal photoreceptor or RPE expression.[9]
- The symptoms experienced and GLP1 receptor distribution are potentially consistent and could provide a possible mechanism for the visual symptoms experienced.
- Medications have shown to associate with visual phenomena. Some examples of medication that produce visual side effects include vasoactive medications, hydroxychloroquine, and ethambutol.[11]
- In conclusion, we describe a case of a bilateral, incongruous, temporary central scotoma visible only under scotopic conditions possibly due to oral semaglutide use. With the popularity of this new medication and mild symptoms, practitioners should be aware of and on the lookout for this and perhaps other possible new associations.

References

1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141

2. Stretton B, Kovoor J, Bacchi S, et al. Weight Loss With Subcutaneous Semaglutide Versus Other Glucagon Like Peptide-1 Receptor Agonists In Type 2 Diabetes: A Systematic Review. *Intern Med J*. Published online May 15, 2023. doi:10.1111/imj.16126

3. The Lancet Regional Health – Western Pacific. Where are the drugs? The scarcity of medications in the Western Pacific. *Lancet Reg Health West Pac*. 2023;31:100728. doi:10.1016/j.lanwpc.2023.100728

4. Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. *Diabetes Care*. 2021;44(1):290-296. doi:10.2337/dc20-1815

5. Bain SC, Klufas MA, Ho A, Matthews DR. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. *Diabetes Obes Metab*. 2019;21(3):454-466. doi:10.1111/dom.13538

6. Lu Z, Suzuki A, Wang D. Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions. *BMC Med Res Methodol*. 2023;23(1):71. doi:10.1186/s12874-023-01885-w

7. Xiao G, Li A. Food and Drug Administration Adverse Event Reports of Diabetic Retinopathy, Macular Edema and Blurred Vision Associated with GLP-1 Receptor Agonist Use. *Invest Ophthalmol Vis Sci*. 2020;61(7):290.

8. Hernández C, Bogdanov P, Corraliza L, et al. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes. *Diabetes*. 2016;65(1):172-187. doi:10.2337/db15-0443

9. Hebsgaard JB, Pyke C, Yildirim E, Knudsen LB, Heeggaard S, Kvist PH. Glucagon-like peptide-1 receptor expression in the human eye. *Diabetes Obes Metab*. 2018;20(9):2304-2308. doi:10.1111/dom.13339

10. Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). *Ophthalmology*. 2016;123(6):1386-1394. doi:10.1016/j.ophtha.2016.01.058

11. Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol optic neuropathy. *Curr Opin Ophthalmol*. 2017;28(6):545-551. doi:10.1097/ICU.0000000000000416

12. Passman RS, Bennett CL, Purpura JM, et al. Amiodarone-associated optic neuropathy: a critical review. *Am J Med*. 2012;125(5):447-453. doi:10.1016/j.amjmed.2011.09.020